News | July 13, 2022
Eversana partners with Compai Pharma to expand commercialisation services across APAC
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
LifeWell Raises USD 80M from OrbiMed to Build Large Scale Healthcare Delivery Platform with Full stack Diagnostics~
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
.jpg)
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
Company is investing more than €100 million in the expansion of the Halle site
Subscribe To Our Newsletter & Stay Updated
